GLOW (GHK-Cu + TB-500 + BPC-157) (70mg)
GLOW is a research peptide blend that combines GHK-Cu, TB-500 (Thymosin Beta-4), and BPC-157 in a single 70 mg vial. Each component has been studied for its regenerative and healing properties across various tissues. By combining all three in one formulation, GLOW aims to synergistically promote tissue repair, inflammation reduction, and wound healing.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
The three peptides in GLOW act through distinct yet complementary biological pathways. **GHK-Cu** acts as a genomic regulator — it activates tissue growth genes and suppresses inflammatory genes. It stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and exhibits antioxidant properties. **TB-500** facilitates cell migration by binding to actin, accelerates angiogenesis, and reduces scar tissue formation. **BPC-157** enhances growth factor signaling (VEGF, PDGF), activates nitric oxide pathways, and promotes fibroblast migration. Together, they create an optimal environment for tissue repair.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~23.3 mg/mL concentration.
- Typical Daily Dose: 2,330 mcg (2.33 mg) once daily for 4 weeks.
- Storage: Lyophilized: −20 °C · after reconstitution: 2–8 °C · within 4 weeks.
Typical Protocol (3 mL = 23.3 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2,330 mcg | 10 Units (0.10 mL) |
Studies report administration once daily subcutaneously. This provides approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection.
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- Inject slowly against the wall of the vial to avoid foaming.
- Gently swirl or rotate until fully dissolved (do not shake vigorously).
- Note reconstitution date and refrigerate at 2–8 °C, protected from light.
- Use within 4 weeks for optimal potency.
Protocol Overview
- Objective: Support comprehensive tissue healing through synergistic mechanisms — collagen synthesis (GHK-Cu), cell migration & angiogenesis (TB-500), local repair & anti-inflammatory action (BPC-157).
- Schedule: Daily subcutaneous injections for 4 weeks, followed by a 2–4 week break.
- Dose: 2,330 mcg (2.33 mg) total blend daily.
- Storage: Lyophilized in freezer · reconstituted in refrigerator · within 4 weeks.
Dosing Protocol
- Daily Dose: 2,330 mcg (10 units / 0.10 mL) stable throughout the cycle.
- Frequency: Once daily (subcutaneously), preferably at a consistent time.
- Cycle Duration: 4 weeks of daily use, followed by a 2–4 week pause.
- Volume: ~0.1 mL per injection, well below the 1.0–1.5 mL comfort threshold for subcutaneous administration.
- Break between cycles: After the cycle, a 4–6 week pause is recommended. This pause allows for evaluation of results and prevention of tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle, a 4–6 week pause is recommended. This pause allows for evaluation of results and prevention of tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C or lower for long-term stability.
- Reconstituted: 2–8 °C continuously · do not freeze reconstituted solution · within 4 weeks.
- Allow frozen vials to reach room temperature before opening.
- Protect from light (amber vial or wrap in foil).
- Inspect before each use · discard if discolored or cloudy.
Important Notes
- Aseptic Technique: Clean vial stopper and skin with separate alcohol pads.
Potential Benefits & Side Effects
Potential Benefits:
- Accelerated wound healing across multiple tissues.
- Anti-inflammatory action and pain reduction.
- Improved tissue quality with reduced fibrosis.
- Multi-tissue regeneration — orthopedic, dermatological, gastrointestinal.
Potential Side Effects:
- Generally very well-tolerated.
- Potential mild injection site reaction (redness, itching).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Angiogenesis & tissue remodeling
GHK-Cu promotes angiogenesis, tissue regeneration, and increases collagen/elastin. Theoretical concern for enhancing existing tumors, though no clinical signal exists.
📄 Life Sci 2012Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010References
- International Journal of Molecular Sciences — Regenerative and protective actions of GHK-Cu (2018)
View Source - Vitamins & Hormones (PubMed) — Thymosin β4 promotes dermal healing (2016)
View Source - Expert Opinion on Biological Therapy — Thymosin β4: a multifunctional regenerative peptide (2012)
View Source - HSS Journal (PMC) — BPC-157 in orthopedic sports medicine (2025)
View Source
External Sources & Regulatory Status
Regulatory Approvals
Compounded blend — Not evaluated as a standalone medicine
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →